Prostate cancer can adapt to androgen deprivation therapy by mutating AR, amplifying/overexpressing AR, upregulating constitutively-active AR splice variants (AR-Vs) that lack the ligand-binding domain, activating AR by androgen-independent mechanisms, and/or increasing intra-tumoral androgen levels through de novo androgen synthesis [4]–[17]. This evidence concerns the gene AR and prostate cancer.